Pegfilgrastim Benefits Elderly Breast Cancer Patients on Chemo

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 12
Volume 11
Issue 12

BOSTON-Pegfilgrastim (Neu-lasta), the longer-lasting analog of the colony-stimulating factor filgrastim (Neupogen), is safe for elderly breast cancer patients receiving myelosuppressive chemotherapy and protects against febrile neutropenia, according to a poster presented at the third meeting of the International Society of Geriatric Oncology (SIOG abstract P-23).

BOSTON—Pegfilgrastim (Neu-lasta), the longer-lasting analog of the colony-stimulating factor filgrastim (Neupogen), is safe for elderly breast cancer patients receiving myelosuppressive chemotherapy and protects against febrile neutropenia, according to a poster presented at the third meeting of the International Society of Geriatric Oncology (SIOG abstract P-23).

Richard S. Harms, PharmD, RPh, manager of oncology professional services at Amgen Inc., Thousand Oaks, California, presented the analysis on behalf of the authors, four researchers from the Pegfilgrastim Study Group.

The investigators retrospectively analyzed pooled data for elderly patients from two key phase III trials of pegfilgrastim. About 13% of patients in these studies were over age 65. The results established that pegfilgrastim once per chemotherapy cycle is as safe and effective as daily filgrastim. Results for patients in the 65-and-over age group were comparable to those of younger patients, and the researchers concluded that the relative risk of neutropenic events was similar.

The risk of febrile neutropenia was significantly lower among the elderly patients given pegfilgrastim, occurring in 15% of patients on pegfilgrastim vs 22% of those on filgrastim. The relative risks of hospitalization and use of an intravenous anti-infective agent also were lower for patients given pegfilgrastim, but not significantly.

Dr. Harms cautioned that the benefit of pegfilgrastim over filgrastim could not be stated conclusively, because the original trials were not designed to establish the superiority of one form of the colony-stimulating factor over the other—only that the two were equivalent. 

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.